Table 3.

Effect Size between EOP Patients and Controls for Markers Assessed by a Single Study

Marker	Study	N EOP patients	N controls	SMD (95% CI)	Z*	P
Albumin	Parellada et al., 2012	34	34	0.195 (-0.325 to 0.717)	0.737	.461
CoQ	Simsek et al., 2016b	20	20	-0.055 (-0.675 to 0.565)	-0.174	.862
Hcy	Parellada et al., 2012	34	34	1.620 (0.990 to 2.249)	5.042	<.001
IFN-gamma	Simsek et al., 2016a	34	34	0.151 (-0.375 to 0.677)	0.562	.574
IL-10	Simsek et al., 2016a	30	26	-0.534 (-1.069 to 1.557)	-1.959	.050
IL-17 alpha	Simsek et al., 2016a	30	26	0.447 (-0.084 to 0.979))	1.649	.099
IL-18	Xu et al., 2016	14	13	0.368 (-0.393 to 1.130)	0.948	.343
IL-18R	Xu et al., 2016	14	13	-1.191 (-2.010 to -0.372)	-2.849	.004
IL-2	Simsek et al., 2016a	30	26	0.515 (-0.019 to 1.048)	1.890	.059
IL-4	Simsek et al., 2016a	30	26	0.073 (-0.452 to 0.598)	0.272	.786
IL-6	Simsek et al., 2016a	30	26	0.194 (-0.332 to 0.721)	0.723	.470
TBARS	Parellada et al., 2012	34	34	0.049 (-0470 to 0.569)	0.186	.852
TNF-alpha	Simsek et al., 2016a	30	26	0.301 (-0.227 to 0.829)	1.117	.264
Transferrin	Parellada et al., 2012	34	34	0.402 (-0.123 to 0.926)	0.150	.134
Uric acid	Parellada et al., 2012	34	34	0.378 (-0.146 to 0.902)	1.413	.158
Vitamin A	Parellada et al., 2012	34	34	0.381 (-0.143 to 0.906)	1.426	.154
Vitamin B12	Parellada et al., 2012	34	34	-0.347 (-0.817 to 0.176)	-1.300	.194
Vitamin E	Parellada et al., 2012	34	34	0.112 (-0.408 to 0.632)	0.423	.673

Abbreviations: CoQ, coenzyme Q; EOP, early onset psychosis; Hcy, homocysteine (plasma); IFN-gamma, interferon gamma; IL, interleukin; SMD, standard mean difference; TBARS, thiobarbituric acid reactive substances; TNF-alpha, tumor necrosis factor alpha.

Significant P values are bold.

* A positive value means that marker is higher in EOP patients than in controls.